Three Indian Drug Makers Selling Lipitor Generics In U.S. Drive Price Down
This article was originally published in PharmAsia News
So many Indian makers of generics are set to market their own versions of Pfizer’s popular Lipitor (atorvastatin) cholesterol drug, both new and old suppliers to the U.S. can expect pressure for lower prices.
You may also be interested in...
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.